NCT00279162

Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis

Calcipotriene Plus Betamethasone Dipropionate Gel Compared to the Gel Vehicle in Scalp Psoriasis, in Patients Receiving Calcipotriene Plus Betamethasone Dipropionate Ointment for Psoriasis Vulgaris of Trunk/Limbs

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: LEO Pharma · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patients will receive either a gel containing both calcipotriene plus betamethasone or gel with no active ingredients as treatment for their scalp psoriasis for 8 weeks. After this time all patients will receive the gel containing both calcipotriene and betamethasone for 44 weeks. In addition, patients will receive an ointment containing both calcipotriene plus betamethasone as treatment for their psoriasis of the trunk and limbs for 52 weeks. The objective is to study the short-term efficacy of the gel, and the short and long-term safety of the gel and the ointment.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Calcipotriene/betamethasone gel and ointment

Timeline

• Start date: 2005-12-01
• Completion: 2007-07-01
• First posted: 2006-01-19
• Last updated: 2025-02-24

Locations

1 site across 1 country: United States